Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Go back to Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa| (NASDAQ: OCGN) | Delayed: 1.23 -0.03 (2.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.26 | 52 Week High | $ | |||
| Open | $1.29 | 52 Week Low | $ | |||
| Day High | $1.30 | P/E | N/A | |||
| Day Low | $1.23 | EPS | $ | |||
| Volume | 4,144,940 | |||||
